• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Tyrosine Kinase Inhibitor
    7 Drugs classified under this drug class

    All the Drug Class Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    partial basket chart

    Tyrosine Kinase Inhibitor. Imatinib 100 mg, 400 mg.
    F.C. TABS: 20, 60 x 100 mg; 10, 30 x
    Doses of 400 mg or 600 mg should be
    admin. once dly., whereas a daily dose
    of 800 mg should be admin. as 400 mg
    ×2/d in the morn. and even.
    Tmt. of adult pts. and child. 3 yrs. of age
    and above with Ph+ chron. myeloid
    leukaemia (Ph+ -CML) in chron. phase
    accelerat. phase or blast crisis. Glivec is
    also indicat. for the tmt. of adult pts.s
    with Kit (CD117) posit. unresect. and/or
    metastat. malignant GI strom. tumour.
    (GIST). Also indicated for the tmt. of :
    Adult pts. with newly diagnosed
    Philadelphia chromos. posit. acute
    lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. Adult pts.
    with relapsed or refract. Ph + ALL as
    monother. Adult pts. with unresect.
    dermatofibrosarcoma protuberans
    (DFSP) and adult pts. with recurrent and/
    or metastat. DFSP who are not eligible
    for surg. Adult pts. with myelodyspiastic/
    myeloproliferative dis.(MDS/MPD) assoc.
    with PDGFR ( platelet - derived growth
    factor recept. ) gene re- arrangements.
    Adult pts. with hypereosinophilic syndr.
    (HES) and/or chronic eosinophilic
    leukaemia (CEL) who have the FIP1L1-
    PDGFRalfa fusion kinase (mutational
    analysis or FISH demonstration fo CHIC2
    allele deletion) and for pts. with HES and/
    or CEL who are FIP1L1-PDGFR alfa fusion
    kinase negative . Adult pts. with aggress.
    systemic mastocytosis (ASM) without the
    D816V c-kit mutation .Adjuvant tmt. of
    adult pts. follow. complete gross resec. of
    Kit (CD117) positive GIST.
    C/I: Hypersens.

    partial basket chart

    Tyrosine Kinase Inhibitor. Axitinib 1 mg, 5 mg.
    F.C. TAB: 28, 56, 60, 180 × 5, 1 mg.
    Recomm. init. oral dose is 5 mg×2/d. approx. 12 hrs. apart with/without food. Should be swallow. whole with a glass of water. If the pt. vomits or misses a dose, an addit. dose should not be taken. The next prescribed dose should be taken at the usual time. See lit.
    Tmt. of advanc. RCC after fail. of one prior syst. therapy.
    C/I: Hypersens.

    partial basket chart

    Tyrosine Kinase Inhibitor. Ruxolitinib Phosphate 5 mg, 10 mg, 15 mg, 20 mg.
    TAB: blist.: 56, bottle.: 60×5, 15, 20mg
    Start. dose:
    MF: The recomm. start. dose: in is 15
    mg ×2/d for pts. with a plat. count
    between 100,000/mm³ and 200,000/
    mm 3 and 20 mg ×2/d for pts. with a
    plat. count of >200,000/mm³.
    PV: The recomm. start. dose of is 10
    Limited inform. to recommend a start.
    dose for pts. with plat. count. between
    50,000/mm³ & <100,000/mm³.
    The max. recomm. start. dose in these
    pts. is 5 mg ×2/d and the pts. should be
    titrated cautious.
    Dose modific.: Doses may be titrat. based on safety & efficacy. Tmt. should be discont. for plat. counts less than 50,000/mm³ or absolute neutrophil counts less than 500/mm³. In PV, tmt. should also be interrupt. when haemoglobin is below
    8 g/dl. After recov. of blood count. above these levels, dosing may be re-started at 5 mg ×2/d and gradual. incr. based on careful. See. lit.
    Myelofibrosis (MF).: Tmt. of dis.-related splenomeg.or sympt. in adult pts. with prim. MF (also known as chron. idiopath. MF), post polycythaem. vera myelofibrosis or post essential thrombocythaem. MF.
    Polycythaem. vera (PV).: Tmt. of adult pts. with PV who are resist. to or intolerant of hydroxyurea.
    C/I: Hypersens. Preg. Lact.

    partial basket chart

    ALK, Tyrosine Kinase Inhibitor. Lorlatinib 25 mg, 100 mg.
    F.C. TABS.: 90, 120×25mg, 30×100mg. 100 mg×1/day orally, with/without food, at the same time each day, until dis. progress. or unacceptab. toxic.
    Swallow tablets whole. If a dose is missed, then the missed dose should be taken, unless the next dose is due within 4 hrs. If vomit. occurs after lorlatinib cont. with the next scheduled dose. 2 doses should not be taken at the same time to make up for a missed dose. See lit.
    Tmt. of adult pts. with metast. NSCLC whose tumors are anaplast. lymphom. kinase (ALK)-positive.
    C/I: Pts. taking strong CYP3A induc., due to the potential for serious hepatotox. Hypers.

    partial basket chart

    Tyrosine Kinase Inhibitor. Erlotinib 100 mg, 150 mg.
    TABS: 30 x 100 mg, 150 mg. Non-small
    cell lung cancer: 150 mg 1 x dly
    without food. Pancreat. cancer: 100 mg
    dly without food in comb. with
    First-line tmt. locally advanced/metastat.
    non-small cell lung cancer (NSCLC) with
    EGFR activat. mutats. Tmt. locally.
    advanced/metastat. NSCLC aft. fail. of at
    least one prior chemother. reg. Monother.
    for maint. tmt. pts with locally advanc./
    metastat. non-small cell lung cancer
    whose disease not progress. aft. 4 cycles of
    platinum-based first-line chemother. In
    comb. with gemcitabine for first-line tmt.
    with locally advanced, unresect./
    metastat. pancreat. cancer.
    C/I: Hypersens. to erlotinib or excips.

    partial basket chart

    Tyrosine Kinase Inhibitor. Nilotinib (HCl monohydrate) 150 mg, 200 mg.
    CAPS: 28, 40, 112, 120 x 200 mg, 28, 112
    x 150 mg.
    Newly diagn. Ph+ CML-CP: recomm.
    dose 300 mg x 2 dly.
    Pts. with Ph+ CML-CP and CML-AP
    resist./intoler. to at least 1 prior ther.
    incl. imatinib: recomm. dose 400 mg x
    2 dly. See lit.
    150 mg, 200 mg: Tmt. adult pts. with newly
    diagn. Ph+ CML in chron. phase.
    200 mg only: Tmt. of Ph+ CML in chron./
    acceler. phase in pts. resist. to/experienc.
    signif. toxicity dur. tmt. imatinib.
    C/I: Hypersens.